Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

In people with Parkinson's disease, neuropsychiatric signs and symptoms are common
throughout the disease course. These symptoms can be disabling and as clinically relevant …

Background In March 2020, the World Health Organization declared a global pandemic due
to the novel coronavirus SARS-CoV-2 and several governments planned a national …

The Parkinson's Progression Markers Initiative (PPMI) has collected more than a decade's
worth of longitudinal and multi-modal data from patients, healthy controls, and at-risk …

Background Parkinson's disease (PD) is one of the common neurodegenerative diseases.
Depression and anxiety are the most common psychiatric symptoms of PD. It is important to …

The relative importance of antimuscarinic anticholinergic medications for Parkinson's
disease (PD) declined after the introduction of levodopa, such that anticholinergic …

Background: Constipation is regarded as one of the prodromal features of Parkinson's
disease (PD) and there is emerging evidence linking gastrointestinal dysfunction and …

Dementia have substantial negative impact on the affected individual, their care partners
and society. Persons living with Parkinson's disease (PwP) are also to a large extent living …

Parkinson disease (PD) used to be considered a nongenetic condition. However, the
identification of several autosomal dominant and recessive mutations linked to monogenic …

Estimates of the risk of dementia in Parkinson's disease (PDD) vary widely. We aimed to
review the incidence of PDD and in a meta‐analysis estimate the pooled annual incidence …